Galderma has signed an agreement to acquire ZO Skin Health for an enterprise value of 1.5 billion USD. The acquisition brings together two complementary, science-backed skincare brands. ZO Skin Health's premium daily multi-step regimens will complement Galderma's Alastin regenerative portfolio focused on peri-procedure support.
The transaction expands Galderma's Dermatological Skincare portfolio in the fast-growing physician-dispensed skincare segment. Galderma's Integrated Dermatology Strategy and global scale are expected to support ZO Skin Health's next phase of growth. The acquisition is expected to be Core EPS neutral in the first full year following closing.
ZO Skin Health, founded by dermatologist Dr. Zein Obagi, recorded net sales of approximately 330 million USD in the last twelve months as of June 2026. The brand is sold through a network of more than 16,500 physician, medical spa and online accounts across more than 40 countries. Terms of the deal were not disclosed, but the acquisition includes 100% of ZO Skin Health.
Galderma, headquartered in Zug, Switzerland, stated the deal strengthens its offering in the medical-grade skincare segment. The acquisition underscores Galderma's commitment to investing in both internal and external opportunities that strengthen its portfolio and support the company's long-term growth.
Source: Wall Street Journal Markets · Summarized by HeadlinesBriefing